Life Sciences

FDA receives first-ever MDMA drug application

The timeline for the Multidisciplinary Association for Psychedelic Studies (MAPS...

FDA Places CARsgen Therapeutics’ CAR-T Cell Therapies o...

CARsgen Therapeutics, a Chinese biotech company, is facing a significant setback...

BMJ Investigation Shines Light on Semaglutide U.K. Mark...

A probe conducted by the British Medical Journal (BMJ) has provided insight into...

Novo Nordisk Foundation’s $260M Initiative Targets Enha...

In a major move, the Novo Nordisk Foundation is allocating $260 million to pione...

Checkpoint Therapeutics Faces FDA Setback, but Optimism...

Checkpoint Therapeutics, headquartered in Waltham, Massachusetts, recently encou...

Pharvaris’ hereditary angioedema medication reduces att...

Pharvaris has reported a significant breakthrough in the treatment of hereditary...

Unveiling Weight Regain Trends in Eli Lilly’s Zepbound ...

Patients taking Eli Lilly’s weight loss drug Zepbound faced a substantial weight...

Bristol Myers’ Opdivo and Cisplatin Combination Achieve...

A notable development has occurred in the initial treatment of colorectal cancer...

Poseida’s Roche-Backed Off-the-Shelf CAR-T Shows Promis...

In response to the FDA’s recent safety review of approved CAR-T therapies, Posei...

NeuroOne Grabs FDA Clearance For Ablation Tech

NeuroOne has now received another agency nod that expands upon the capabilities ...

FDA Approves Gene Therapies for Sickle Cell Treatment

In a move that marks a significant advancement in the treatment of sickle cell d...

Microscopic “super bots” repair neural wound model

In a recent development, scientists have brought science fiction to life by crea...

Lilly’s Jaypirca leads the leukemia trail with FDA appr...

In the highly competitive landscape of BTK inhibitors for blood cancer treatment...

Merus Faces Setback Following Interim Report for Lung C...

Merus, a biopharmaceutical company, confronted a significant setback following a...

Merck’s Evobrutinib Encounters Setbacks in MS Trials Am...

Merck KGaA’s foray into the competitive BTK inhibitor space has hit a roadblock,...

Roche’s $2.7 Billion Move into the Obesity Market Acqui...

Roche has made a resounding entry into the obesity market with a whopping upfron...